Fertility after chemotherapy for ovarian germ cell tumours.
Gonadal function was assessed in 17 women who successfully completed chemotherapy with the POMB/ACE regimen (cisplatin, vincristine [Oncovin], methotrexate, bleomycin/actinomycin D, cyclophosphamide, etoposide) for ovarian germ cell tumours, and had a remaining ovary and uterus. A 20-year-old girl has not yet recovered menstruation 5 months off chemotherapy. All the remaining women whose mean age at start of chemotherapy was 21 (9-38) are now menstruating with a median time of recovery of 41/2 months after completion of chemotherapy. Five women have so far conceived after chemotherapy resulting in three full term normal deliveries of healthy infants, one termination of pregnancy, two miscarriages and one continuing pregnancy. Gonadal function does not appear to be permanently impaired in the majority of patients receiving POMB/ACE chemotherapy for ovarian germ cell tumours.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003561:Cytarabine; D003609:Dactinomycin / Q000009:adverse effects / Q000627:therapeutic use; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005298:Fertility; D006801:Humans; D008598:Menstruation; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000503:physiopathology*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D010053:Ovary / Q000503:physiopathology*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D003561:Cytarabine; D001761:Bleomycin; D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D008727:Methotrexate